

5

REMARKS

After entry of this amendment, claims 10, 11, and 20-33 are pending in the present application. Amendment of claims 10 and 11 is inherent in the original claims. New claims 20-33 are supported by the disclosure of preferred substituent groups on pages 9, lines 27- 35; page 10, lines 1-2; page 10, line 27- page 13, line 37; and the a, b, and j groups of original claim 1. No matter was added by these amendments.

Should the Examiner have any questions or comments regarding this amendment or the application in general, he is invited to call the undersigned at (860) 686-0349. The Commissioner is hereby authorized to any fees that may be required, or credit any overpayment, to Deposit Account No. 16-1445.

15

Respectfully submitted,
Pfizer, Inc.



Lisa A. Samuels
Reg. No. 43,080

20 Date: September 10, 2003

25 Pfizer, Inc.
Eastern Point Road, MS 8260-1611
Groton, CT 06340

Customer ID No.: 28523

30